Wave Life Sciences is a clinical-stage genetic medicines company. Co. has a pipeline of programs. Co.'s primary programs are designed to treat genetic diseases, which include: WVE-N531 (splicing), its exon 53 molecule for the treatment of Duchenne muscular dystrophy; WVE-006 (editing), its SERPINA1 molecule for the treatment of alpha-1 antitrypsin deficiency; WVE-003 (silencing), its mutant huntingtin single nucleotide polymorphism three molecule for the treatment of Huntington's disease; and WVE-004 (silencing), its C9orf72 molecule for the treatment of C9orf72-associated amyotrophic lateral sclerosis and frontotemporal dementia. The WVE average annual return since 2015 is shown above.
The Average Annual Return on the WVE average annual return since 2015 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether WVE average annual return since 2015 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the WVE average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|